MNPR insider transaction filings
Monopar Therapeutics — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen MNPR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Vu Quan Anh — Chief Financial Officer | Option exercise (M): 1,228 · Tax withholding (F): 507 @ $92.59 · Option exercise (M): 1,228 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 12,873 · Tax withholding (F): 4,084 @ $92.59 · Option exercise (M): 12,873 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 5,254 · Tax withholding (F): 2,309 @ $92.59 · Option exercise (M): 5,254 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Sweeny Nicole — Director | Grant/award (A): 1,284 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 6,732 · Tax withholding (F): 1,972 @ $54.79 · Option exercise (M): 6,732 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 3,514 · Tax withholding (F): 1,571 @ $54.79 · Option exercise (M): 3,514 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Rodriguez Susan — CCSO | Grant/award (A): 48,728 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Robinson Chandler — Chief Executive Officer, Director | Other (J): 62,815 @ $0 | EDGAR |
| 2026-01-05 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 8,724 · Tax withholding (F): 2,558 @ $65.30 · Option exercise (M): 8,724 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 4,326 · Tax withholding (F): 1,889 @ $65.30 · Option exercise (M): 4,326 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | RIOUX PATRICE | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Vu Quan Anh — Chief Financial Officer | Purchase (P): 1,500 @ $69.95 | EDGAR |
| 2025-12-19 | 4 | KLAUSNER ARTHUR J — Director | Sale (S): 4,660 @ $67.06 · Sale (S): 461 @ $68.09 | EDGAR |
| 2025-12-17 | 4 | Hendricks Diane — 10% owner | Other (J): 43,499 @ $0 | EDGAR |
| 2025-12-17 | 4 | KLAUSNER ARTHUR J — Director | Other (J): 7,710 @ $0 | EDGAR |
| 2025-12-08 | 4 | Cittadine Andrew — Chief Operating Officer | Grant/award (A): 8,969 (derivative) @ $0 · Grant/award (A): 13,919 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Talukdar Lavina — Director | Grant/award (A): 2,924 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Vu Quan Anh — Chief Financial Officer | Grant/award (A): 7,135 (derivative) @ $0 · Grant/award (A): 9,826 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Robinson Chandler — Chief Executive Officer, Director | Grant/award (A): 16,753 (derivative) @ $0 · Grant/award (A): 49,133 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Anderson Raymond — Director | Grant/award (A): 2,924 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Tsuchimoto Kim R — Director | Grant/award (A): 2,924 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | STARR CHRISTOPHER M — Director | Grant/award (A): 2,924 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | KLAUSNER ARTHUR J — Director | Grant/award (A): 2,924 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 4,327 · Tax withholding (F): 1,896 @ $81.67 · Option exercise (M): 4,327 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 8,726 · Tax withholding (F): 2,646 @ $81.67 · Option exercise (M): 8,726 (derivative) @ $0 | EDGAR |
| 2025-09-26 | 4 | Tactic Pharma LLC — 10% owner Robinson Chandler — Chief Executive Officer, Director Brown Michael J O'Halloran Thomas V. Mazar Andrew Paul | Sale (S): 550,229 @ $63.61 | EDGAR |
| 2025-07-16 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise/expiry (X): 16,800 @ $0.01 · Sale (S): 16,800 @ $40.00 · Option exercise/expiry (X): 16,800 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Tsuchimoto Kim R — Director | Option exercise/expiry (X): 8,904 @ $0.01 · Sale (S): 8,904 @ $40.00 · Option exercise/expiry (X): 4,200 (derivative) @ $0 · Option exercise/expiry (X): 4,704 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | STARR CHRISTOPHER M — Director | Option exercise/expiry (X): 16,800 @ $0.01 · Sale (S): 16,800 @ $40.00 · Option exercise/expiry (X): 16,800 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 13,344 · Tax withholding (F): 5,865 @ $35.78 · Option exercise (M): 13,344 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 6,863 · Tax withholding (F): 2,990 @ $35.78 · Option exercise (M): 6,863 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Tactic Pharma LLC — 10% owner Robinson Chandler — Chief Executive Officer, Director Brown Michael J O'Halloran Thomas V. Mazar Andrew Paul | Sale (S): 33,334 @ $35 | EDGAR |
| 2025-04-02 | 4 | Cittadine Andrew — Chief Operating Officer | Option exercise (M): 1,791 · Tax withholding (F): 744 @ $36.41 · Option exercise (M): 1,791 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 4,106 · Tax withholding (F): 1,204 @ $36.41 · Option exercise (M): 4,106 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Robinson Chandler — Chief Executive Officer, Director | Option exercise (M): 6,002 · Tax withholding (F): 1,759 @ $31.70 · Grant/award (A): 85,759 (derivative) @ $0 · Grant/award (A): 79,899 (derivative) @ $0 · Option exercise (M): 6,002 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Cittadine Andrew — Chief Operating Officer | Grant/award (A): 43,445 (derivative) @ $0 · Grant/award (A): 40,581 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Talukdar Lavina — Director | Grant/award (A): 5,683 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Anderson Raymond — Director | Grant/award (A): 11,365 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Tsuchimoto Kim R — Director | Grant/award (A): 11,365 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | STARR CHRISTOPHER M — Director | Grant/award (A): 11,365 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | KLAUSNER ARTHUR J — Director | Grant/award (A): 11,365 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Vu Quan Anh — Chief Financial Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Monopar Therapeutics
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MNPR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →